Document Type : Original Research


1 Department of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehan, Iran

3 Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

4 Department of Pathology, Yas Women Hospital, Tehran University of Medical Sciences, Tehran, Ian



Background & Objective: GATA3 immunohistochemistry has been described as a highly sensitive marker in determining carcinomas of breast and urothelial origin. In the gynecologic system, it can be used as a marker to diagnose mesonephric or mesonephric-like carcinomas and trophoblastic tumors. The present study was performed to determine the diagnostic value of GATA3 in gynecological adenocarcinomas.
Methods: A total of 187 samples from different types of endometrial, endocervical, and ovarian carcinomas were analyzed for intensity and percentage of GATA3 expression in tumor cells. The relationship between GATA3 expression and clinicopathological parameters was investigated.
Results: A total of 187 patients including 101 ovarian, 77 endometrial, and 9 endocervical adenocarcinomas were investigated. Weak and focal expression of this marker was observed in 5. 1% (4/77) endometrial, 12.9% (13/101) ovarian, and 11.1% (1/9) endocervical adenocarcinomas. The mean H score in all subtypes was less than 10.6 (2-35). There was no statistically significant correlation between GATA3 expression in tumor cells with clinical stage, and tumor recurrence or metastasis.
Conclusion: GATA3 is infrequently, weak, or focally expressed in most of the common gynecological adenocarcinomas.


Main Subjects

  1. Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, Nakano H. Histological classification of ovarian cancer. Med Electron Micros. 2003;36:9-17. [DOI:10.1007/s007950300002] [PMID]
  2. Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, et al. Epithelial ovarian cancer: An overview. J Transl Med. 2014;3 (1):1. [DOI:10.5528/wjtm.v3.i1.1] [PMID]
  3. El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, et al. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020;68:109539. [DOI:10.1016/j.cellsig.2020.109539] [PMID]
  4. Liu D, Zhang X-X, Li M-C, Cao C-H, Wan D-Y, Xi B-X, et al. C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nat Commun. 2018;9 (1):1739. [DOI:10.1038/s41467-018-03590-5] [PMID]
  5. Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam physician. 2016;93 (6):468-74.
  6. Sorosky JI, Joel I. Cáncer endometrial. Obstet Gynecol. 2012;120:383-97. [DOI:10.1097/AOG.0b013e3182605bf1] [PMID]
  7. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120 (2 Part 1):383-97. [DOI:10.1097/AOG.0b013e3182605bf1] [PMID]
  8. Bulletins-Gynecology CoP, Committee tSoGOsCP. Practice bulletin no. 149: endometrial cancer. Obstet Gynecol. 2015;125 (4):1006-26. [DOI:10.1097/] [PMID]
  9. Stolnicu S, Park KJ, Kiyokawa T, Oliva E, McCluggage WG, Soslow RA. Tumor typing of endocervical adenocarcinoma: contemporary review and recommendations from the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2021;40 (2 Suppl 1):S75. [DOI:10.1097/PGP.0000000000000751] [PMID]
  10. Bray F, Carstensen B, Møller H, Zappa M, Zˇakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomark Prev. 2005;14 (9):2191-9. [DOI:10.1158/1055-9965.EPI-05-0231] [PMID]
  11. Kurman RJ, Carcangiu ML, Herrington CS. World Health Organisation classification of tumours of the female reproductive organs: International agency for research on cancer; 2014.
  12. Houghton O, Jamison J, Wilson R, Carson J, McCluggage WG. p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection. Histopathology. 2010;57 (3):342-50. [DOI:10.1111/j.1365-2559.2010.03632.x] [PMID]
  13. McCluggage WG. Recent developments in non-HPV-related adenocarcinomas of the lower female genital tract and their precursors. Adv Anat Pathol. 2016;23 (1):58-69. [DOI:10.1097/PAP.0000000000000095] [PMID]
  14. Park KJ, Kiyokawa T, Soslow RA, Lamb CA, Oliva E, Zivanovic O, et al. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Am J Surg Pathol. 2011;35 (5):633-46. [DOI:10.1097/PAS.0b013e31821534b9] [PMID]
  15. Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol. 2000;157 (4):1055-62. [DOI:10.1016/S0002-9440(10)64619-6] [PMID]
  16. Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, Nishimura R. Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol. 2007;31 (5):664-72. [DOI:10.1097/01.pas.0000213434.91868.b0] [PMID]
  17. Kusanagi Y, Kojima A, Mikami Y, Kiyokawa T, Sudo T, Yamaguchi S, Nishimura R. Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Pathol. 2010;177 (5):2169-75. [DOI:10.2353/ajpath.2010.100323] [PMID]
  18. Ko LJ, Engel JD. DNA-binding specificities of the GATA transcription factor family. Molecul Cell Biol. 1993. [DOI:10.1128/mcb.13.7.4011-4022.1993] [PMID]
  19. Merika M, Orkin SH. DNA-binding specificity of GATA family transcription factors. Molecul Cell Biol. 1993;13 (7):3999-4010. [DOI:10.1128/mcb.13.7.3999-4010.1993] [PMID]
  20. Najafabadi MK, Mirzaeian E, Montazerin SM, Tavangar AR, Tabary M, Tavangar SM. Role of GATA3 in tumor diagnosis: A review. Pathol Res Pract. 2021;226:153611. [DOI:10.1016/j.prp.2021.153611] [PMID]
  21. Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138 (1):57-64. [DOI:10.1309/AJCP5UAFMSA9ZQBZ] [PMID]
  22. Liang Y, Heitzman J, Kamat AM, Dinney CP, Czerniak B, Guo CC. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014;45 (7):1466-72. [DOI:10.1016/j.humpath.2014.02.023] [PMID]
  23. Terzic T, Mills AM, Zadeh S, Atkins KA, Hanley KZ. GATA3 expression in common gynecologic carcinomas: a potential pitfall. Int J Gynecol Pathol. 2019;38 (5):485-92. [DOI:10.1097/PGP.0000000000000541] [PMID]
  24. Clark BZ, Beriwal S, Dabbs DJ, Bhargava R. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas. Am J Clin Pathol. 2014;142 (1):64-71. [DOI:10.1309/AJCP8H2VBDSCIOBF] [PMID]
  25. Lowry JA, Atchley WR. Molecular evolution of the GATA family of transcription factors: conservation within the DNA-binding domain. J Molecul Evol. 2000;50:103-15. [DOI:10.1007/s002399910012] [PMID]
  26. Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol. 2010;222 (1):42-9. [DOI:10.1002/jcp.21943] [PMID]
  27. Reiswich V, Schmidt CE, Lennartz M, Höflmayer D, Hube-Magg C, Weidemann S, et al. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors. Pathobiology. 2023:1-14. [DOI:10.1159/000527382] [PMID]
  28. Lee Y, Choi S, Kim H-S. Comprehensive immunohistochemical analysis of mesonephric marker expression in low-grade endometrial endometrioid carcinoma. Int J Gynecol Pathol. 2023:10. 1097. [DOI:10.1097/PGP.0000000000000976]